The US Food & Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to United States-based Cepheid's Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19, it was reported on Saturday.
The test is intended to operate on any of the company's more than 23,000 automated GeneXpert Systems worldwide, with a detection time of around 45 minutes.
The company is to start shipping the test from next week.
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA